This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Companies Likely to Bid for Onyx Pharma

SOUTH SAN FRANCISCO ( TheStreet) -- Onyx Pharmaceuticals (ONXX) has rejected Amgen's (AMGN - Get Report) takeout offer of $120 per share in cash and said it will seek additional bidders. I believe there are five key potential suitors for Onyx, each with a unique motivation to gain control of the company's most important asset -- the blood cancer drug Kyprolis.

Here, then, is a rundown of the five companies I believe will seek to acquire Onyx in the coming weeks:

1. Amgen

While Amgen has oncology products, a bid for Onyx is less about synergies and more about seeking growth. Right now, Amgen's only late-stage blood cancer product is blinatumamab, which is in phase II studies for acute lymphoblastic leukemia. Acquiring Onyx would make Amgen an instant and significant player in the blood cancer treatment market, as well as further expand its existing footprint in the solid tumor market.

Amgen is also the slowest-growing large-cap biotech company, which is especially problematic as peer companies Biogen Idec (BIIB), Celgene (CELG - Get Report), and Gilead Sciences (GILD - Get Report) are all growing much faster or about to enter high-growth periods. In the eyes of many investors, Amgen isn't even considered a biotech company any longer, meaning it isn't rewarded with the growth multiple of its competitors. An acquisition of Onyx might change that perception for the better.

2. Bayer

Bayer is already partnered with Onyx. The two companies co-market the liver and kidney cancer drug Nexavar and the colon cancer drug Stivarga. This gives Bayer a significant advantage over other potential suitors because it stands to gain the most from potential cost-saving synergies. It also means Bayer might be able to offer a higher price for Onyx and keep the dilutive effect on earnings to a minimum. Of course, the "Bayer is going to buy Onyx" speculation has been chatted up by Wall Street investors for years without a deal ever being coming to fruition. One has to wonder of Bayer is really that motivated to participate in the auction process for Onyx.

3. Celgene

Celgene has the most complementary group of cancer-drug assets of all the potential Onyx suitors. Celgene already has a significant presence in blood cancer with the currently approved drugs Thalomid, Revlimid and Pomalyst. In addition, Celgene has shown a recent interest in acquiring new blood-cancer drugs with differing mechanisms of action like the purchase of Avila Therapeutics for its BTK inhibitor and the recent collaboration with Morphosys to gain access to a monoclonal antibody that targets CD38.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
ONXX $0.00 0.00%
AMGN $163.58 0.00%
CELG $113.47 0.00%
GILD $101.38 0.00%
JNJ $99.58 0.00%


DOW 17,826.30 -279.47 -1.54%
S&P 500 2,081.18 -23.81 -1.13%
NASDAQ 4,931.8150 -75.9760 -1.52%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs